The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | PRO4All: elucidating patient-reported outcome measures in lung cancer
Alberto Servetto, MD, PhD, University of Naples Federico II, Naples, Italy, explores the identification and characteristics of lung cancer-specific patient-reported outcome measures (PROMs) used in oncology clinical trials. As part of the PRO4All project, multiple lung cancer-specific PROMs were identified from various sources and assessed for recall period. The findings highlight the need for standardized PROMs in lung cancer trials, enabling more consistent assessment of patient outcomes. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
